StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM)

Analysts at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

CEL-SCI Price Performance

NYSE CVM opened at $0.27 on Wednesday. The stock’s 50-day moving average price is $0.27 and its two-hundred day moving average price is $0.48. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66. The company has a market cap of $22.38 million, a PE ratio of -0.55 and a beta of 0.95. CEL-SCI has a 1 year low of $0.18 and a 1 year high of $2.39.

Hedge Funds Weigh In On CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Geode Capital Management LLC increased its position in CEL-SCI Co. (NYSE:CVM) by 9.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 612,861 shares of the company’s stock after buying an additional 53,879 shares during the period. Geode Capital Management LLC owned 0.96% of CEL-SCI worth $650,000 at the end of the most recent reporting period. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.